New generation Alzheimer’s diagnostics
A new generation of ELISAs provides standardized, automated analysis of beta-amyloid (Aß) peptides (Aß 1-42 and Aß 1-40) and total tau (T-tau) proteins in cerebrospinal fl uid (CSF), facilitating diagnosis of Alzheimer’s disease in its early stages. The concentrations of these biomarkers reflect the Alzheimer’s-specific neuropathological changes in the brain. A significant decrease in Aß 1-42 is observed as many as 5 to 10 years before the start of cognitive changes. Aß 1-40 remains unchanged. The determination of the ratio Aß 1-42 to Aß 1-40 increases the efficiency of early diagnostics and might help to discriminate Alzheimer’s disease from vascular dementia. The concentrations of T-tau and phosphorylated tau (P-tau) increase when patients develop advanced neurodegeneration and cognitive impairment. Th e Aß 1-42, Aß 1-40 and T-tau ELISAs have been developed by Euroimmun in collaboration with ADx Neurosciences. They are based on a sandwich principle employing well-characterized capture antibodies. This matrix-independent methodology ensures extremely high consistency in results. The assays are CE-certified and include lyophilized calibrators for added convenience and precision. The procedures are highly standardized and can be automated on Euroimmun analysers and other open ELISA platforms.
Supplier: EUROIMMUN AG
Website:
